Clinical Trial Update: Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing exenatide once weekly and dapagliflozin versus exenatide and dapagliflozin with a placebo extension; completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Dapagliflozin (dapagliflozin)
• EXENATIDE (EXENATIDE)

Snippet

Sponsor: AstraZeneca | Conditions: Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2017-09-08